financetom
Business
financetom
/
Business
/
Canadian packaging firm Transcontinental Q3 revenue beats expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Canadian packaging firm Transcontinental Q3 revenue beats expectations
Sep 4, 2025 2:34 PM

Overview

* Transcontinental Inc ( TCLAF ) Q3 revenue falls 2.2% yr/yr, but beats analyst expectations, per LSEG data

* Adjusted EPS for Q3 beats estimates, rising 16.7% yr/yr

Outlook

* Transcontinental expects organic growth in Packaging Sector earnings for fiscal 2025

* Company anticipates higher earnings growth in Retail Services and Printing Sector

* Transcontinental plans significant cash flow generation to reduce net indebtedness

* Company's investments in flexible packaging to drive long-term growth

Result Drivers

* PACKAGING SECTOR DECLINE - Revenue decreased due to sale of industrial packaging operations and weaker demand, impacting the Packaging Sector

* RETAIL SERVICES GROWTH - Retail Services and Printing Sector saw a 4.5% revenue increase, driven by book printing activities

* COST REDUCTION - Improved adjusted operating earnings margin in Packaging Sector due to cost reduction initiatives and favorable exchange rate

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat C$684.40 C$679

Revenue mln mln (6

Analysts

)

Q3 Beat C$0.7 C$0.69

Adjusted (6

EPS Analysts

)

Q3 Miss C$58.90 C$59.10

Adjusted mln mln (3

Net Analysts

Income )

Q3 Net C$38.70

Income mln

Q3 C$57.40

Operatin mln

g

Earnings

Q3 C$109

Operatin mln

g

Earnings

Before

Deprecia

tion &

Amortiza

tion

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the non-paper containers & packaging peer group is "buy"

* Wall Street's median 12-month price target for Transcontinental Inc ( TCLAF ) is C$24.00, about 15.5% above its September 3 closing price of C$20.27

* The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved